The importance of treating cardiometabolic risk factors in patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 5, Issue 1, 2008, Pages 9-14

  Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Abdominal obesity; Adipokines; Cardiometabolic risk; Type 2 diabetes; Visceral fat

Indexed keywords

ADIPOCYTOKINE; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

ABDOMINAL OBESITY; ABDOMINAL PAIN; ABNORMAL FECES; ADIPOSE TISSUE; ANOREXIA; BLOATING; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEFECATION URGENCY; DIABETES MELLITUS; DIARRHEA; DYSLIPIDEMIA; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER DYSFUNCTION; METABOLIC DISORDER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULSE RATE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TASTE DISORDER;

ABDOMINAL FAT; ADIPOKINES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 41949090925     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.002     Document Type: Review

References (70)

1. Diabetes UK. Diabetes: State of the Nations 2006: Diabetes UK, 2007.
2. International Diabetes Federation. Diabetes Atlas: Executive summary. 2003.
3. Adler AI, Stevens RJ, Neil A et al. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-9.
4. Kothari V, Stevens RL, Adler AI et al. UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study Risk Engine. Stroke 2002;33:1776-81.
5. Han TS, van-Leer EM, Seidell JC et al. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995;311:1401-05.
6. Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.
7. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
8. Wahrenberg H, Hertel K, Leijonhufvud BM et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005;330:1363-4.
9. Valverde AM, Benito M, Lorenzo M. The brown adipose cell: a model for understanding the molecular mechanism of insulin resistance. Acta Physiol Scand 2005;183:59-73.
10. Trayhum P. The biology of obesity. Proc Nutr Soc 2005;64:31-8.
11. Arner P. Insulin resistance in type 2 diabetes - role of the adipokines. Curr Mol Med 2005;5:333-9.
12. Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-71.
13. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27(suppl 3):S25-S28.
14. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
15. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-84.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
17. Saghizadeh M, Ong JM, Garvey WT et al. The expression of TNF-alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996;97:1111-16.
18. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997;272:971-6.
19. de Alvaro C, Teruel T, Hernandez R et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK dependent manner. J Biol Chem 2004;279:17070-8.
20. Rotter V, Nagaev I, Smith U. lnterleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin resistant subjects. J Biol Chem 2003;278:45777-84.
21. Al-Khalili L, Bouzakri K, Glund S et al. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006;20:3364-75.
22. Glund S, Deshmukh A, Long YC et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 2007;56:1630-7.
23. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
24. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005;6:13-21.
25. Schober F, Neumeier M, Weigert J et al. Low molecular weight adiponectin negatively correlates with waist circumference and monocytic IL-6 release. Biochem Biophys Res Commun 2007;361:968-73.
26. Palanivel R, Fang X, Park M et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 2007;75:148-57.
27. Bacha F, Saad R, Gungor N et al. Adiponectin in youth. Relationship to visceral adiposity, insulin sensitivity and beta cell function. Diabetes Care 2004;27:547-52.
28. Combs TP, Berg AH, Obici S et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-81.
29. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004;143:9-21.
30. Nguyen MT, Satoh H, Favelyukis S et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280:35361-71.
31. Krauss RM. Lipids and lipoprotein in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.
32. Jiang XC, Moulin P, Quinet E et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991;266:4631-9.
33. de Grooth GJ, Klerkx AHEM, Stroes ES et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74.
34. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.
35. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
36. Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH et al. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 2007;37:90-8.
37. Pastors JG, Warshaw H, Daly A et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002;25:608-13.
38. Sigal RJ, Kenny GP, Wasserman DH et al. Physical activity/exercise and type 2 diabetes. Diabetes Care 2004;27:2518-39.
39. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
40. Nathan DM, Buse JB, Davidson MB] et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
41. IDF Clinical Guidelines Task Force. Global guidelines for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
42. National Institute for Clinical Excellence. Management of type 2 diabetes: management of blood glucose. 2002.
43. Goo AK, Carson DS, Bjelajac A. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. J. Fam Pract 1996;42:612-18.
44. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.
45. Wright A, Burden ACF, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
46. National Institute for Clinical Excellence. Guidance on the use of glitazones for the treatment of type 2 diabetes. Technology Appraisal 63, 2003.
47. Higgs ER, Krentz AJ. ABCD position statement on glitazones. Pract Diab Int 2004;24:1-3.
48. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
49. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
50. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
51. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007;298:1180-8.
52. JBS2. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1-v52.
53. National Institute for Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal 94, 2006.
54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
55. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002;84:53-7.
56. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
57. Keech A, Simes R, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
58. Taylor AJ, Sullenberger LE, Lee HJ ,Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17.
59. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004: CD004094.
60. Hsieh CJ, Wang PW, Liu RT et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005;67:78-83.
61. Padwal R, Majumdar S. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7.
62. Hung YJ, Chen YC, Pei D et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabet Med 2005;22:1024-30.
63. Kim DM, Yoon SJ, Ahn CW et al. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004;66:S139-S144.
64. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005;16:297-313.
65. Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
66. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
67. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
68. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
69. Ordovas JM. Identification of a functional polymorphism at the adipose fatty acid binding protein gene (FABP4) and demonstration of its association with cardiovascular disease: a path to follow. Nutr Rev 2007;65:130-4.
70. Furuhashi M, Tuncman G, Gorgun CZ et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-65.